Liposomes in the Supplement Industry: Promise, Problems, and the Truth Behind the Claims

Liposomes in the Supplement Industry: Promise, Problems, and the Truth Behind the Claims

Introduction

The nutraceutical and supplement industry is in a perpetual quest for technologies that boost the absorption and efficacy of bioactive compounds. Among these, liposomal delivery systems have attracted intense interest. Liposomes are spherical vesicles with a phospholipid bilayer, resembling cell membranes, and have long been used in pharmaceutical drug delivery to improve solubility, stability, and bioavailability of otherwise poorly absorbed molecules. The recent surge in liposomal supplements ranging from vitamins (e.g., C, D, B12) to botanicals (curcumin, resveratrol, glutathione, and more), reflects the hope that this pharma technology can translate to more potent, effective over-the-counter products. However, despite promising science, the use of liposomes in the supplement industry is rife with technical challenges, overblown marketing, and sometimes outright misinformation.

What Are Liposomes, and Why Use Them?

Liposomes are microscopic vesicles, typically 50–500 nm in diameter, composed of one or more phospholipid bilayers surrounding an aqueous core. This structure allows them to encapsulate both hydrophilic and hydrophobic compounds, theoretically protecting them from degradation in the digestive tract and enhancing their passage through biological membranes such as intestine lining. In pharmaceuticals, liposomes have enabled improved delivery of chemotherapeutics (e.g., Doxil, Ambisome), vaccines, and antifungal. The supplement industry claims similar benefits for nutrients and plant extracts, touting superior absorption and enhanced bioavailability.

The Promise and The Problems

1. True Advances in Bioavailability

Some research supports the use of liposomes for increasing oral bioavailability. For example, liposomal vitamin C has been shown to produce higher plasma levels than conventional formulations in some studies, and liposomal curcumin has demonstrated improved absorption and tissue delivery in animal models. However, such benefits are highly formulation-specific, and results may not generalize across products or ingredients.

2. Major Issues with Liposomal Supplements

Despite the scientific promise, there are several issues:

  • Lack of Standardization: Unlike pharmaceutical liposomes, which undergo strict quality control, supplement liposomes vary widely in particle size, lamellarity (number of bilayers), stability, encapsulation efficiency, and shelf-life. Many commercial products are not rigorously characterized and tested.
  • Questionable Manufacturing Quality: Numerous analyses have found that a significant proportion of supplements labeled as "liposomal" do not contain true liposomes or contain only a small fraction of the active ingredient within liposomal structures. Some products are simply emulsions or micelles, not bona fide liposomes.
  • Stability Concerns: Liposomes are prone to oxidation, aggregation, and breakdown, especially in acidic or high-temperature environments typical of storage and transport. Unstable products may deliver no actual advantage over traditional forms.
  • No Regulatory Definition: The FDA and other regulatory bodies have not set standards for what constitutes a liposomal supplement, leaving the door open for misleading labeling and marketing.

3. False Claims and Regulatory Scrutiny

A pervasive problem in the market is exaggerated or outright false claims. Many brands promise "10x," "100x," or "maximum absorption" based on limited or non-existent pre-clinical or clinical evidence. Several supplements advertise proprietary liposomal technology without any published data or third-party validation.

4. Are liposomes really non-toxic

Although many liposomal components claim to be non-toxic, however:

  • Most adverse effects stem from the body’s processing of large lipid amounts, especially by macrophages.
  • PEGylated (stealth) liposomes can cause hypersensitivity (infusion) reactions in some patients, likely due to immune responses to the PEG coating.
  • Some reactions seen in animal studies translate to the clinic, especially with Doxil® (PEGylated doxorubicin liposome).
  • Accelerated Blood Clearance (ABC) phenomenon: Repeat administration of PEGylated liposomes can trigger immune responses that accelerate their removal from the bloodstream, possibly reducing efficacy and increasing liver uptake.
  • Macrophage overload: Accumulation of foamy/vacuolated macrophages in organs (liver, spleen, lungs) is seen, but so far has no clear adverse consequence in humans at therapeutic doses.
  • Local irritation: Some products can cause site reactions or granulomatous inflammation, especially with subcutaneous or local delivery.

Conclusion and Recommendations

Liposomes hold genuine promise as a delivery system for pharmaceuticals and certain nutraceuticals, with some evidence of improved bioavailability for select ingredients. However, the supplement industry’s embrace of liposomal technology is far ahead of the science and regulation. Quality varies drastically, and many products make unsupported claims about their superiority. Until standards and third-party validation become the norm, consumers should be cautious, seek out products with published data or independent verification, and view extraordinary marketing claims with skepticism.

References

1. Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015). New developments in liposomal drug delivery. Chemical Reviews, 115(19), 10938–10966.
2. Immordino, M. L., Dosio, F., & Cattel, L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications. International Journal of Nanomedicine, 1(3), 297–315
3. Gopi S, Balakrishnan P. Evaluation and clinical comparison studies on liposomal and non-liposomal ascorbic acid (vitamin C) and their enhanced bioavailability. J Liposome Res. 2021 Dec;31(4):356-364. doi: 10.1080/08982104.2020.1820521. Epub 2020 Oct 6. PMID: 32901526.
4. Liu W, Zhai Y, Heng X, Che FY, Chen W, Sun D, Zhai G. Oral bioavailability of curcumin: problems and advancements. J Drug Target. 2016 Sep;24(8):694-702. doi: 10.3109/1061186X.2016.1157883. Epub 2016 Mar 17. PMID: 26942997.
5. Baldrick P. Nonclinical Testing Evaluation of Liposomes as Drug Delivery Systems. Int J Toxicol. 2023 Mar-Apr;42(2):122-134. doi: 10.1177/10915818221148436. Epub 2022 Dec 26. PMID: 36571279.
6. Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology, 6, 286.
7. Akbarzadeh, A., et al. (2013). Liposome: classification, preparation, and applications. Nanoscale Research Letters, 8(1), 102.
8. Schiborr, C., et al. (2020). Bioavailability of Curcumin: Problems and Promises. Nutrients, 12(12), 3899.
9. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics. 2017 Mar 27;9(2):12. doi: 10.3390/pharmaceutics9020012. PMID: 28346375; PMCID: PMC5489929.

Back to blog